Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria
PHASE4CompletedINTERVENTIONAL
Enrollment
52
Participants
Timeline
Start Date
September 30, 2003
Study Completion Date
November 30, 2004
Conditions
Type 2 DiabetesMicroalbuminuria
Interventions
DRUG
irbesartan
Trial Locations (1)
2820
Steno Diabetes Center, Gentofte Municipality
All Listed Sponsors
lead
Steno Diabetes Center Copenhagen
OTHER
NCT00320879 - Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria | Biotech Hunter | Biotech Hunter